Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.
Volatility and Risk
Connect Biopharma has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500. Comparatively, Northwest Biotherapeutics has a beta of -0.67, meaning that its share price is 167% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Connect Biopharma and Northwest Biotherapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 5 | 1 | 2.86 |
| Northwest Biotherapeutics | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Connect Biopharma and Northwest Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -122.29% | -97.07% |
| Northwest Biotherapeutics | -2,931.73% | N/A | -79.26% |
Insider and Institutional Ownership
58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 0.0% of Northwest Biotherapeutics shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 2.4% of Northwest Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Connect Biopharma and Northwest Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $60,000.00 | 2,172.12 | -$55.48 million | ($1.15) | -1.80 |
| Northwest Biotherapeutics | $1.38 million | 225.70 | -$60.16 million | ($18.23) | -0.01 |
Connect Biopharma has higher earnings, but lower revenue than Northwest Biotherapeutics. Connect Biopharma is trading at a lower price-to-earnings ratio than Northwest Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Connect Biopharma beats Northwest Biotherapeutics on 11 of the 15 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
